Factors and Challenges in Understanding SARS-CoV-2 RNA Levels, Symptoms, and Transmissibility—Reply

Author(s):  
Erin Chung ◽  
James P. Hughes ◽  
Helen Y. Chu
Keyword(s):  
1981 ◽  
Vol 256 (6) ◽  
pp. 3135-3140
Author(s):  
P. Tolstoshev ◽  
R.A. Berg ◽  
S.I. Rennard ◽  
K.H. Bradley ◽  
B.C. Trapnell ◽  
...  

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Kerina Duri ◽  
◽  
Simbarashe Chimhuya ◽  
Exnevia Gomo ◽  
Privilege Tendai Munjoma ◽  
...  

Introduction Despite being a leading infectious cause of childhood disability globally, testing for cytomegalovirus (CMV) infections in pregnancy is generally not done in Sub-Sahara Africa (SSA), where breastfeeding practice is almost universal. Whilst CMV and human immunodeficiency virus (HIV) are both endemic in SSA, the relationship between antenatal plasma CMV-DNA, HIV-1-RNA levels and HIV-1-mother to child transmission (MTCT) including pregnancy outcomes remains poorly described. Methods Pregnant women at least 20 weeks’ gestational age at enrolment were recruited from relatively poor high-density suburbs in Harare, Zimbabwe. Mother-infant dyads were followed up until 6 months postpartum. In a case–control study design, we tested antenatal plasma CMV-DNA levels in all 11 HIV-1 transmitting mothers, as well as randomly selected HIV-infected but non-transmitting mothers and HIV-uninfected controls. CMV-DNA was detected and quantified using polymerase chain reaction (PCR) technique. Antenatal plasma HIV-1-RNA load was quantified by reverse transcriptase PCR. Infants’ HIV-1 infection was detected using qualitative proviral DNA-PCR. Predictive value of antenatal plasma CMV-DNAemia (CMV-DNA of > 50 copies/mL) for HIV-1-MTCT was analyzed in univariate and multivariate regression analyses. Associations of CMV-DNAemia with HIV-1-RNA levels and pregnancy outcomes were also explored. Results CMV-DNAemia data were available for 11 HIV-1 transmitting mothers, 120 HIV-infected but non-transmitting controls and 46 HIV-uninfected mothers. In a multivariate logistic regression model, we found a significant association between CMV-DNAemia of > 50 copies/mL and HIV-1 vertical transmission (p = 0.035). There was no difference in frequencies of detectable CMV-DNAemia between HIV-infected and -uninfected pregnant women (p = 0.841). However, CMV-DNA levels were higher in immunosuppressed HIV-infected pregnant women, CD4 < 200 cells/µL (p = 0.018). Non-significant associations of more preterm births (< 37 weeks, p = 0.063), and generally lower birth weights (< 2500 g, p = 0.450) were observed in infants born of HIV-infected mothers with CMV-DNAemia. Furthermore, in a multivariate analysis of HIV-infected but non-transmitting mothers, CMV-DNAemia of > 50 copies/mL correlated significantly with antenatal plasma HIV-1-RNA load (p = 0.002). Conclusion Antenatal plasma CMV-DNA of > 50 copies/mL may be an independent risk factor for HIV-1-MTCT and higher plasma HIV-1-RNA load, raising the possibility that controlling antenatal CMV-DNAemia might improve infant health outcomes. Further studies with larger sample sizes are warranted to confirm our findings.


1991 ◽  
Vol 32 (8) ◽  
pp. 1333-1339
Author(s):  
RJ Warren ◽  
DL Ebert ◽  
A Mitchell ◽  
PJ Barter

Author(s):  
Sandra Van der Auwera ◽  
Sabine Ameling ◽  
Matthias Nauck ◽  
Henry Völzke ◽  
Uwe Völker ◽  
...  

1992 ◽  
Vol 122 (4) ◽  
pp. 864-870 ◽  
Author(s):  
Béatrice le Moullac ◽  
Patricia Gouache ◽  
Fanny Bleiberg-Daniel

Sign in / Sign up

Export Citation Format

Share Document